Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation TORONTO, April 10, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a bioph…
Author of the article:
for a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, muscular and structural inju…